<?xml version="1.0" encoding="UTF-8"?>
<p>During the last decades, the frequency of fungal infections has increased because of human immunodeficiency virus infection and more intensive and cytotoxic chemotherapies
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>. In AIDS, oncology and transplantation patients, 
 <italic>Candida</italic> still one of the major opportunistic pathogens
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0003" ref-type="bibr">
  <sup>3</sup>
 </xref>. Options for treatment of severe fungal infections are primarily amphotericin B, azole compounds and echinocandins
 <xref rid="CIT0004" ref-type="bibr">
  <sup>4</sup>
 </xref>. Although amphotericin B and its lipid formulations decrease the morbidity and mortality, they must be given intravenously, are extremely expensive and still carry significant infusion-related toxicity. Echinocandins, one of the first-line therapy in neutropenic patients reveal a high antifungal activity against 
 <italic>Candida spp</italic>
 <xref rid="CIT0005" ref-type="bibr">
  <sup>5</sup>
 </xref>. However, resistance emergence has been described for 
 <italic>C. albicans</italic> and the haplo√Ød yeast 
 <italic>C. glabrata</italic>
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>. Furthermore, elevated MICs have been reported in the case of 
 <italic>C. parapsilosis</italic>.
</p>
